Clinical trial data for Pfizer’s maternal vaccine to protect babies from RSV support the vaccine’s safety and efficacy, according to a vote by an FDA advisory committee. The FDA could soon approve the vaccine. But a popular social media post makes misleading claims about the trial findings.
Issues: RSV
Q&A on RSV Maternal Vaccine and Antibody Candidates to Protect Infants
Nearly all children get sick from respiratory syncytial virus, or RSV, by the age of 2, and last year, there was a notable surge in RSV-associated hospitalizations. But the Food and Drug Administration is now considering approval of a vaccine and a monoclonal antibody aimed at protecting infants from this common virus.
Q&A on RSV Vaccine Candidates for Older Adults
RSV Surge in Children Likely Caused by ‘Immunity Gap,’ Not COVID-19 Vaccine
Hospitals across the country are seeing a spike of respiratory syncytial virus infections among children. Experts say the spike is most likely caused by an immunity gap created by the lack of exposure to the virus over the past couple of years. There’s no evidence the pediatric COVID-19 vaccine is the cause, as viral posts falsely claim.